Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Copolymer 1 as therapy for multiple sclerosis: the cons.

R W Baumhefner1, W W Tourtellotte, K Syndulko

  • 1Neurology Service, VA Wadsworth Medical Center, Los Angeles, CA 90073.

Neurology
|July 1, 1988
PubMed
Summary

Copolymer 1 (COP-1) did not improve neurologic function or reduce inflammation in multiple sclerosis (MS) patients. Intra-blood-brain-barrier (BBB) IgG synthesis, a marker of MS inflammation, remained unchanged in this preliminary study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A service evaluation following the implementation of computer guided consultation software to support primary care reviews for chronic obstructive pulmonary disease.

NPJ primary care respiratory medicine·2025
Same author

Development and initial psychometric properties of the Warwick-Edinburgh Mental Wellbeing Scale-Intellectual Disability version.

Journal of intellectual disability research : JIDR·2023
Same author

The feasibility and impact of implementing a computer-guided consultation to target health inequality in Asthma.

NPJ primary care respiratory medicine·2023
Same author

Development of optimised tissue-equivalent materials for proton therapy.

Physics in medicine and biology·2023
Same author

Transdifferentiated rat pancreatic progenitor cells (AR42J-B13/H) respond to phenobarbital in a rat hepatocyte-specific manner.

Toxicology·2016
Same author

The Budget Impact of Duoresp® Spiromax® (Budesonide + Formoterol Fumarate Dihydrate) Compared With Symbicort® Turbohaler® for the Management of Asthma and Chronic Obstructive Pulmonary Disease in the United Kingdom: Impact on Health Care Costs and Inhalation Technique.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016

Area of Science:

  • Neuroimmunology
  • Neurology
  • Immunology

Background:

  • Intra-blood-brain-barrier (BBB) IgG synthesis is a hallmark of multiple sclerosis (MS), indicating active inflammation.
  • This synthesis is linked to plasma cells within or near demyelinating plaques.
  • Measuring BBB IgG synthesis can serve as a therapeutic goal for MS treatment.

Purpose of the Study:

  • To evaluate the efficacy of copolymer 1 (COP-1) in reducing intra-blood-brain-barrier (BBB) IgG synthesis in MS patients.
  • To assess the impact of COP-1 on clinical parameters and inflammatory demyelination in MS.

Main Methods:

  • A preliminary trial involving five severely disabled MS patients.
  • Patients received COP-1 via intramuscular or subcutaneous doses for two months.

Related Experiment Videos

  • Intra-blood-brain-barrier (BBB) IgG synthesis was monitored alongside clinical assessments.

    • Main Results:

    • COP-1 treatment did not show beneficial effects on neurologic function.
    • No significant reduction in inflammatory demyelination was observed.
    • Intra-blood-brain-barrier (BBB) IgG synthesis levels remained unchanged during the study period.

    Conclusions:

    • Copolymer 1 (COP-1) did not demonstrate therapeutic benefit in this small cohort of MS patients.
    • Modulating intra-blood-brain-barrier (BBB) IgG synthesis may not be effectively achieved with COP-1 at the tested dosages.
    • Further research is needed to identify effective therapies targeting MS-associated inflammation.